Jylamvo (Methotrexate)

Methotrexate blocks the enzyme dihydrofolate reductase, which is essential for converting folate into its active form. This interruption reduces the synthesis of DNA, RNA, and proteins, limiting the proliferation of rapidly dividing cells, including immune cells that drive inflammation and cancer cells.

The specific dose of Jylamvo is determined by the prescribing clinician based on the patient’s condition, disease severity, renal and hepatic function, and other individual factors. Only a qualified healthcare professional should set the dosing regimen.

Methotrexate is classified as Pregnancy Category X, meaning it is contraindicated in pregnancy due to a high risk of fetal malformations and miscarriage. It is also not recommended while breastfeeding because it can be excreted in breast milk and affect the infant.

To place an order, submit an enquiry on the Jylamvo product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with biologic DMARDs, methotrexate (Jylamvo) is a small‑molecule oral agent that is generally less expensive and has a well‑established safety profile when monitored appropriately. It is often used as first‑line therapy or in combination with biologics to enhance overall disease control.

Jylamvo should be stored at temperatures below 25 °C, in its original packaging, protected from moisture and direct sunlight. Do not store in areas with high humidity or extreme heat to maintain product stability.

Jylamvo is taken orally, usually with a full glass of water. Depending on the prescribing plan, it may be taken once weekly or as directed by the healthcare provider. Patients should follow the exact schedule and any accompanying folic acid supplementation instructions.

Serious risks include severe liver toxicity, bone‑marrow suppression leading to pancytopenia, pulmonary fibrosis, and life‑threatening infections. Patients should be monitored regularly for liver enzymes, blood counts, and respiratory symptoms, and any alarming signs should prompt immediate medical evaluation.

Jylamvo is contraindicated in pregnant women, individuals with severe hepatic or renal impairment, uncontrolled infections, and patients receiving live vaccines. It should also be avoided in those with known hypersensitivity to methotrexate or any of the tablet excipients.